Serina Therapeutics director Jay Venkatesan acquires 589 common shares valued at $1,048.42

Serina Therapeutics Inc

Serina Therapeutics Inc

SER

0.00
  • Serina Therapeutics director Jay Venkatesan reported an increase in common stock ownership to 231,705 shares held indirectly through a legacy trust.
  • The position rose through conversion into 224,152 common shares priced at USD 2.25.
  • Venkatesan also purchased 589 common shares at USD 1.78, bringing direct holdings to 589 shares.
  • Separately, he received stock options for 15,250 shares with an exercise price of USD 1.98.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001413350-26-000004), on June 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.